German chemical giant BASF has reportedly engaged in preliminary discussions this year with its peer Evonik regarding a potential transaction, which market insiders characterize as an acquisition of Evonik by BASF. These discussions were reported by financial news services Dealreporter and Mergermarket, citing multiple sources familiar with the matter. However, both BASF and Evonik have declined to comment on the speculation, with BASF stating it does not discuss market rumors.
The likelihood of a finalized deal in the short term is considered low due to several constraints. BASF is currently undergoing a significant restructuring, including plans to independently list its Agricultural Solutions business, with an IPO anticipated by mid-2027. The company is also focused on reducing its net debt, which stood at $17.12 billion at the end of the first half of 2026, and has launched a share buyback program of up to $1 billion. Analysts, such as Chetan Udeshi from JPMorgan, believe an acquisition of Evonik would be improbable given BASF's current financial priorities and alternative strategic options.
A key factor in any potential acquisition would be the RAG-Stiftung, Evonik's largest shareholder, which holds approximately 44% of the company's shares. The foundation has indicated intentions to reduce its stake over time, aiming for about 25.1%. While initial market reaction saw Evonik's shares rise by as much as 4.8% on the news, both BASF and Evonik shares closed down slightly on the day the rumors surfaced. The potential transaction faces significant regulatory hurdles, including antitrust review by authorities like the European Commission, given the considerable overlap in business areas such as specialty chemicals and additives, and the industrial significance of combining two major German chemical companies.
From a financial perspective, BASF has a market capitalization of approximately $46 billion, compared to Evonik's roughly $8.1 billion. BASF's net debt and negative free cash flow in the first half of 2026 further highlight its capital constraints. Insiders suggest BASF will not pursue major acquisitions before the IPO of its Agricultural Solutions business. The European chemical sector as a whole is facing pressures from declining competitiveness, global overcapacities, and increasing competition, making a potential consolidation seem strategically reasonable in the long term, though any major factory closures resulting from a merger could face political challenges.
